Rani Therapeutics Holdings Inc Cl A (RANI) Stock Price, Quote & News

Company Profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes...

Industry: Biotechnology

Sector: Healthcare

Phone: 408 457 3700

Website: www.ranitherapeutics.com

Address:

2051 Ringwood Avenue, San Jose, United States

Makingmillions192 Aug. 24 at 1:15 PM

$LEXX BOOM 💥 🤯 https://www.accessnewswire.com/newsroom/en/consumer-and-retail-products/dehydratechtm-enhanced-amycretin-and-retatrutide-yield-significant-abs-1210744 $LLY $NVO $VIK $RANI

0 · Reply

KaShing01 Aug. 24 at 1:10 PM

$RANI

0 · Reply

Mandalo Aug. 24 at 8:28 AM

$RANI and $SANOFI.NSE Check out this article from TipRanks | Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI) and Sanofi (OtherSNYNF) | https://tipranks.onelink.me/WJho/xzbdfb9f

1 · Reply

Mandalo Aug. 24 at 4:29 AM

WHAT MAKES $RANI STAND OUT FROM THE CROWD Rani Therapeutics represents a transformative platform play, shifting the valuation model from a single-drug gamble to a high-upside tech engine. By enabling oral delivery of biological drugs via its innovative RaniPill, the company dramatically expands its potential market while significantly lowering biological risk. List of comparable sucessful platforms: $REGN $HALO $IONS $MRNA $RXRX $CADL

2 · Reply

Makingmillions192 Aug. 23 at 1:00 PM

$LEXX Prior to GLP-1s, Lexaria evaluated DehydraTECH-CBD across multi-week human hypertension trials lasting up to 5 weeks. Hypertension Clinical Studies (HYPER-H21-1 & HYPER-H23-1) Demonstrated sustained blood pressure reductions without participants building a tolerance to the drug. PK data showed consistent daily blood plasma levels, proving DehydraTECH is safe for daily, long-term therapeutic regimens. The main difference in this study will be transitioning to tablets. Lexaria uses capsules in trials for speed and cost, but licensing partners like Novo Nordisk or Eli Lilly will produce final tablet formats. Proving DehydraTECH retains its superior absorption (AUC and C_{max}) in tablets ensures a seamless technology transfer for commercial manufacturing. If Human Study #7 succeeds, peer GLP-1 licensing comps and consensus biotech targets price $LEXX between $30 and $50+ per share as major buyout/royalty valuations re-rate the micro-float. $VIK $RANI $LLY $NVO

1 · Reply

Mandalo Aug. 23 at 4:13 AM

$RANI $NVO Jesper Høiland’s appointment as Head of Strategy leverages his extensive Novo Nordisk executive background to position Rani Therapeutics for a transformative GLP-1 partnership. Having led Novo’s U.S. operations, Høiland possesses deep C-suite access and commercial expertise in metabolic therapies. He was specifically brought in to shape strategy for the RaniPill® HC platform, which demonstrated successful oral delivery of semaglutide in preclinical trials. As big pharma races to replace weight-loss injections with oral alternatives, Høiland bridges Rani’s technology with global leaders. Following recent licensing momentum and partnering talks, his network directly enables high-stakes dealmaking, making a licensing agreement with Novo Nordisk a realistic strategic milestone.

2 · Reply

USAEquityResearch Aug. 23 at 12:30 AM

$RANI 📊 USAEquityResearch ▲ 0.88 (+3.41%) Trend: Bullish 📈 RSI (14): 61.8 — strong momentum, approaching overbought MACD: bullish, above signal line and rising Volume: normal 📌 Key Levels Resistance: 0.92 | Support: 0.77 20-MA: 0.81 | 50-MA: 0.77 💼 Fundamentals Mkt Cap: $123.66M FCF: $-8.87M (-0.08/sh) Total Debt: $3.55M D/E: 7.4 📉 Options (exp 2026-10-16) ATM IV: 123.4% | Skew: +120.3% (put-heavy) P/C Ratio: 0.08 🐂 Bullish lean Max Pain: 0.50 Call wall: 1.00 | Put wall: 0.50 Educational content only. Not financial advice. Full data, options chain & financials: https://usaequityresearch.com/stocks/RANI

0 · Reply

Makingmillions192 Aug. 22 at 11:06 PM

$LEXX 🧠 NEW YALE STUDY BULLISH FOR LEXARIA 🚨 Major news from Yale published in PNAS shows Ozempic relies heavily on brain neuron activation for long-term fat loss. It’s not just about gut suppression—GLP-1s MUST hit the brain to sustain weight loss! Why this massive for Lexaria: 💊 Brain Biodistribution: LEXX is actively studying brain tissue delivery in GLP-1-A26-1! 💊 Absorption Matters: Superior bioavailability = stronger CNS delivery & persistence. 💊 Perfect Timing: Adds massive scientific tailwinds right before Human Study #7 top-line PK data drops! When Big Pharma looks for tech that maximizes GLP-1 brain delivery & absorption, DehydraTECH is sitting on the throne. ⚡ Supply locked on a 1.65M micro-float. Load up before next week! 💸🚀 $VKTX $LLY $NVO $RANI #LEXX #GLP1 #Biotech #DehydraTECH #Wegovy #yale https://www.sciencedaily.com/releases/2026/08/260820002436.htm

0 · Reply

wavw Aug. 21 at 8:07 PM

$RANI higher highs

0 · Reply

Makingmillions192 Aug. 21 at 4:29 PM

$LEXX Alright time to wake up from this Friday morning snooze fest with a couple red bulls ⚡️🏎️💨 🚨LEXX IS A TICKING TIME BOMB FOR NEXT WEEK! 🚀🔥 The setup going into next week is pure perfection on this 1.65M micro-float: ⚡ Human Study #7 Readout (GLP-1 vs. Wegovy): Dosing wrapped, blood analysis complete. Top-line steady-state PK data is due ANY DAY NOW! ⚡ Active MTAs In Motion: Fresh deal signed with PegBio + ongoing PharmaCo MTA testing! ⚡ Animal Studies (GLP-1-A26-1 & A26-2): Brain biodistribution + Retatrutide/Amycretin data coming Q3! ⚡ Zero Pre-Data Dilution: Nasdaq cleared, tight float intact, and management chose NOT to discount offer! 130k+ volume absorbed sideways—supply is locked. Once top-line data hits, there won't be any shares left to buy! 💸💊 $RANI $LLY $NVO $VIK #LEXX #GLP1 #Biotech #Catalysts #DehydraTECH

2 · Reply

Rani Therapeutics initiated with a Buy at Chardan

2026-08-16T14:06:16.000Z - 8 days ago

Rani Therapeutics reports Q2 EPS (4c), consensus (5c)

Aug 13, 2026, 4:05 PM EDT - 10 days ago

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

Aug 13, 2026, 4:00 PM EDT - 10 days ago

Rani Therapeutics Holdings Earnings release: Q2 2026

Aug 13, 2026, 4:00 PM EDT - 10 days ago

Rani Therapeutics Holdings Quarterly report: Q2 2026

Aug 12, 2026, 2:30 PM EDT - 11 days ago

Rani Therapeutics Holdings Transcript: Canaccord Genuity's 46th Annual Growth Conference

Aug 10, 2026, 8:00 AM EDT - 14 days ago

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

Jul 20, 2026, 4:05 PM EDT - 4 weeks ago

Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2026-07-15T12:40:48.000Z - 5 weeks ago

Rani Therapeutics reports initial data from RT-114 study

Jul 15, 2026, 8:00 AM EDT - 5 weeks ago

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

2026-07-09T20:15:21.000Z - 6 weeks ago

Rani Therapeutics announces research, development collaboration with PegBio

Jul 9, 2026, 4:05 PM EDT - 6 weeks ago

Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates

2026-06-29T12:20:41.000Z - 2 months ago

Rani Therapeutics appoints Nicholas Maestas as CFO

TPST

Jun 29, 2026, 8:00 AM EDT - 2 months ago

Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer

May 28, 2026, 11:00 AM EDT - 3 months ago

Rani Therapeutics Holdings Transcript: AGM 2026

May 26, 2026, 8:00 AM EDT - 3 months ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules

May 15, 2026, 4:05 PM EDT - 3 months ago

Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition

May 15, 2026, 7:00 AM EDT - 3 months ago

Rani Therapeutics Holdings Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

Rani Therapeutics Holdings Earnings release: Q1 2026

May 12, 2026, 4:05 PM EDT - 3 months ago

Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Rani Therapeutics Holdings Proxy statement: Proxy filing

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Rani Therapeutics Holdings Proxy statement: Proxy filing

Apr 9, 2026, 7:00 AM EDT - 4 months ago

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

2026-04-01T11:31:50.000Z - 5 months ago

Rani Therapeutics price target lowered to $5 from $9 at Canaccord

Mar 26, 2026, 4:30 PM EDT - 5 months ago

Rani Therapeutics Holdings Earnings Call Transcript: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 5 months ago

Rani Therapeutics Holdings Annual report: Q4 2025

Mar 26, 2026, 4:30 PM EDT - 5 months ago

Rani Therapeutics Holdings Earnings release: Q4 2025

Mar 26, 2026, 4:05 PM EDT - 5 months ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

Mar 25, 2026, 4:53 PM EDT - 5 months ago

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

Mar 19, 2026, 4:05 PM EDT - 5 months ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

2026-01-28T12:15:42.000Z - 7 months ago

Rani Therapeutics promotes Javadi to Chief Technical Officer

Jan 28, 2026, 7:00 AM EST - 7 months ago

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

2026-01-08T12:10:14.000Z - 8 months ago

Rani Therapeutics initiates Phase 1 study of RT-114 RaniPill

Jan 8, 2026, 7:00 AM EST - 8 months ago

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen

Nov 24, 2025, 4:05 PM EST - 9 months ago

Rani Therapeutics to Participate in the Evercore Healthcare Conference

2025-11-07T22:15:16.000Z - 10 months ago

Rani Therapeutics files to sell 42.63M shares of Class A common stock for holder

Nov 7, 2025, 7:00 AM EST - 10 months ago

Rani Therapeutics Holdings Registration statement: Registration Filing

Nov 6, 2025, 4:30 PM EST - 10 months ago

Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

Nov 6, 2025, 7:00 AM EST - 10 months ago

Rani Therapeutics Holdings Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Rani Therapeutics Holdings Quarterly report: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 10 months ago

Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

Oct 23, 2025, 4:05 PM EDT - 10 months ago

Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors

Oct 23, 2025, 4:01 PM EDT - 10 months ago

Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Oct 20, 2025, 9:42 AM EDT - 11 months ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CELC CRMD RAPT

Oct 17, 2025, 7:48 AM EDT - 11 months ago

Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma

Oct 17, 2025, 7:31 AM EDT - 11 months ago

Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Oct 17, 2025, 7:30 AM EDT - 11 months ago

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing

Aug 8, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Holdings Registration statement: Registration Filing

Aug 7, 2025, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Rani Therapeutics Holdings Earnings release: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Rani Therapeutics Holdings Quarterly report: Q2 2025

Jul 15, 2025, 9:00 AM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

Jul 14, 2025, 5:00 AM EDT - 1 year ago

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

Jul 3, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Holdings Registration statement: Registration Filing

May 19, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Announces Research Agreement with Chugai

May 13, 2025, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

May 13, 2025, 9:30 AM EDT - 1 year ago

Rani Therapeutics Holdings Quarterly report: Q1 2025

May 13, 2025, 9:30 AM EDT - 1 year ago

Rani Therapeutics Holdings Earnings release: Q1 2025

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Rani Therapeutics Holdings Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Rani Therapeutics Holdings Annual report: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Rani Therapeutics Holdings Earnings release: Q4 2024

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

Mar 25, 2025, 6:00 PM EDT - 1 year ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Dec 4, 2024, 12:55 PM EST - 1 year ago

Rani Therapeutics Holdings Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 18, 2024, 4:10 PM EST - 1 year ago

Rani Therapeutics Holdings Transcript: Stifel 2024 Healthcare Conference

Nov 14, 2024, 1:15 PM EST - 1 year ago

Rani Therapeutics Holdings Transcript: UBS Global Healthcare Conference 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Rani Therapeutics Holdings Quarterly report: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Rani Therapeutics Holdings Earnings release: Q3 2024

Oct 15, 2024, 8:30 AM EDT - 2 years ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

Oct 8, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

Sep 18, 2024, 11:30 AM EDT - 2 years ago

Rani Therapeutics Holdings Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 3, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Participate in September Investor Conferences

Aug 13, 2024, 3:30 PM EDT - 2 years ago

Rani Therapeutics Holdings Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 6, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

Aug 6, 2024, 6:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Quarterly report: Q2 2024

Aug 6, 2024, 6:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Earnings release: Q2 2024

Jul 29, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Participate in August Investor Conferences

Jul 22, 2024, 8:30 AM EDT - 2 years ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

Jun 24, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Transcript: Investor Update

Jun 24, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Press release: Investor Update

Jun 24, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Slides: Investor Update

Jun 24, 2024, 7:00 AM EDT - 2 years ago

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

May 20, 2024, 2:30 PM EDT - 2 years ago

Rani Therapeutics Holdings Transcript: H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 14, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics to Participate in May Investor Conferences

May 9, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

May 6, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

May 6, 2024, 7:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Quarterly report: Q1 2024

May 6, 2024, 7:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Earnings release: Q1 2024

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing

Apr 17, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics Holdings Proxy statement: Proxy Filing

Mar 20, 2024, 4:30 PM EDT - 2 years ago

Rani Therapeutics Holdings Earnings Call Transcript: Q4 2023

Mar 20, 2024, 4:30 PM EDT - 2 years ago

Rani Therapeutics Holdings Annual report: Q4 2023

Mar 20, 2024, 4:30 PM EDT - 2 years ago

Rani Therapeutics Holdings Earnings release: Q4 2023

Mar 20, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

Mar 15, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Dec 14, 2023, 8:00 AM EST - 2 years ago

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

Nov 8, 2023, 4:05 PM EST - 3 years ago

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

Nov 8, 2023, 4:00 PM EST - 3 years ago

Rani Therapeutics Holdings Quarterly report: Q3 2023

Oct 19, 2023, 4:05 PM EDT - 3 years ago

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

Oct 12, 2023, 4:05 PM EDT - 3 years ago

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

Sep 18, 2023, 8:00 AM EDT - 3 years ago

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

Makingmillions192 Aug. 24 at 1:15 PM

$LEXX BOOM 💥 🤯 https://www.accessnewswire.com/newsroom/en/consumer-and-retail-products/dehydratechtm-enhanced-amycretin-and-retatrutide-yield-significant-abs-1210744 $LLY $NVO $VIK $RANI

0 · Reply

KaShing01 Aug. 24 at 1:10 PM

$RANI

0 · Reply

Mandalo Aug. 24 at 8:28 AM

1 · Reply

Mandalo Aug. 24 at 4:29 AM

2 · Reply

Makingmillions192 Aug. 23 at 1:00 PM

1 · Reply

Mandalo Aug. 23 at 4:13 AM

2 · Reply

USAEquityResearch Aug. 23 at 12:30 AM

0 · Reply

Makingmillions192 Aug. 22 at 11:06 PM

0 · Reply

wavw Aug. 21 at 8:07 PM

$RANI higher highs

0 · Reply

Makingmillions192 Aug. 21 at 4:29 PM

2 · Reply

Hi1254 Aug. 21 at 4:12 PM

$RANI Before the water boils and bubbles, it slowly starts to get loud! You can notice that here at $RANI too.

0 · Reply

KaShing01 Aug. 21 at 1:50 PM

$RANI Another upgrade PT $11 news https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-rani-therapeutics-stock-rating-at-buy-93CH-4871461

0 · Reply

wavw Aug. 21 at 1:48 PM

$RANI if you sell you’ll be loser. Simple. $7.

2 · Reply

APRadek Aug. 21 at 10:35 AM

$RANI

0 · Reply

samuraicoder Aug. 21 at 5:35 AM

$RANI

0 · Reply

wavw Aug. 20 at 8:02 PM

$RANI it didn’t go below .85. Good sign

1 · Reply

Makingmillions192 Aug. 20 at 7:41 PM

$LEXX Hoping we get human study data in the morning or news and then we have a mega squeeze going into Monday 🔥 A 1bn headline NR with major pharma also would be great 💰 $RANI $LLY $NVO

0 · Reply

MoneyMacG Aug. 20 at 7:33 PM

$BETR $VSAT $GTLB $DQ $RANI ×

1 · Reply

Mandalo Aug. 20 at 3:48 PM

$RANI Climbing slowley back into the green. 😇🤑👍

0 · Reply

ebk81 Aug. 20 at 3:22 PM

$RANI PT/ faire value @ 6$ why you anyone sell..

2 · Reply

wavw Aug. 20 at 2:54 PM

$RANI next move will be huge…

0 · Reply

Makingmillions192 Aug. 20 at 12:52 PM

$LEXX No dilution, no discount offering, and another clean pre-market session! Passing on an equity raise after a high-volume float rotation signals strong management confidence ahead of the Study #7 readout 💪 Absorption Confirmed: Yesterday’s 130k volume spike wasn’t a pre-funded institutional dump or an offering setup. It was pure market absorption—shares shifting into firmer hands without breaking the upward trend 💰 Tight Structure Maintained: By foregoing a discounted raise, management keeps the ~1.65M share float completely intact. Any upcoming demand shock will hit an extremely constrained supply 🔥 The Binary Setup Is Locked: LEXX is heading into the clinical readout on its own terms, with full Nasdaq compliance secured and the DehydraTECH GLP-1 thesis untouched 💊 With the runway clear and the float tight, the focus remains entirely on the incoming top-line data! 🐂 📈 💥 $RANI $LLY $VKTX $NVO

1 · Reply

Market Cap	109.02M
Revenue (ttm)	1.63M
Net Income (ttm)	-29.67M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,820.25%
Debt to Equity Ratio	0.00

Volume	708,300
Avg Vol	846,462
Day's Range	N/A - N/A
Shares Out	123.88M
Stochastic %K	73%
Beta	0.78
Analysts	Strong Sell
Price Target	$7.40